MYL5 (myosin light chain 5) is a regulatory myosin light chain protein with diverse cellular functions. Structurally, MYL5 contains evolutionarily conserved motifs important for calcium binding and phosphorylation 1, localized to the muscle myosin complex where it regulates muscle contraction. Beyond its classical role in skeletal muscle physiology, MYL5 functions as a chr4-associated nuclear protein that regulates gene transcription 2. Muscle physiology studies demonstrate MYL5 expression changes during strength training-induced muscle hypertrophy and recovery, suggesting involvement in transcriptional regulation of muscle adaptation 3. MYL5 expression is associated with insulin resistance response to exercise, with differential patterns between young and older subjects 4. Clinically, MYL5 dysregulation has emerged as a cancer-associated marker. In cervical carcinoma, MYL5 overexpression correlates with metastasis and poor survival; MYL5 bidirectionally regulates hypoxia-inducible factor-1α (HIF-1α) to promote cancer progression 2. In breast cancer, high MYL5 expression associates with favorable prognosis and correlates with immune cell infiltration patterns 5. MYL5 appears co-expressed with other genes in colon cancer prognostic networks 6. Genomically, MYL5 maps to chromosome 4.3 1 and has been identified in deletions associated with retinal degeneration 7 and ring chromosome 4 syndrome 8, suggesting potential developmental importance.